Quick Answer
Senti Biosciences Holdings, Inc. reported R&D Expense of $37.59 million for fiscal year 2025.
Senti Biosciences Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $37.59M | +9.4% |
| 2024 | $34.36M | +6.9% |
| 2023 | $32.15M | +14.2% |
| 2022 | $28.14M | +28.2% |
| 2021 | $21.96M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.52M | +21.5% | +4.9% |
| June 30, 2025 | $10.03M | +9.6% | +8.1% |
| March 31, 2025 | $9.28M | +5.7% | +7.2% |
| September 30, 2024 | $8.65M | -4.8% | -5.4% |
| June 30, 2024 | $9.15M | +33.1% | +4.2% |
| March 31, 2024 | $8.78M | +24.4% | -3.4% |
| September 30, 2023 | $9.09M | +39.5% | +32.2% |
| June 30, 2023 | $6.88M | -25.6% | -2.6% |
- Senti Biosciences Holdings, Inc. showed an increase of +9.4% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Senti Biosciences Holdings, Inc.’s r&d expense has grown by 71.2% (from $21.96 million to $37.59 million).
- The most recent figure is from Senti Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: